Effects of insulin administration on β-cell function in subjects at high risk for type I diabetes mellitus

• Published in: Metabolism, clinical and experimental Vol. 45; no. 7; pp. 873 - 875
• Main Authors: Rodríguez-Villar, C., Conget, I., González-Clemente, J.M., Vidal, J., Navarro, P., Casamitjana, R., Gomis, R.
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.07.1996; Elsevier
• Subjects: Adolescent; Adult; Biological and medical sciences; Case-Control Studies; Diabetes Mellitus, Type 1 - etiology; Diabetes Mellitus, Type 1 - prevention & control; diet-related diseases; Hormones. Endocrine system; human nutrition; Humans; Hypoglycemia - etiology; Hypoglycemia - prevention & control; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - adverse effects; Injections, Subcutaneous; Insulin - metabolism; Insulin Secretion; Insulin, Isophane - administration & dosage; Insulin, Isophane - adverse effects; Islets of Langerhans - drug effects; Islets of Langerhans - physiology; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Prediabetic State - drug therapy; Prediabetic State - physiopathology; Risk Factors; Safety; Time Factors; Endocrinopathy; Human; Urine; Immunopathology; Pancreatic hormone; Excretion; Peptides; Langerhans islet; Autoimmune disease; Statistical study; Insulin; C-Peptide; Prevention; Protein hormone; Treatment; B-Cell; Risk factor; Insulin dependent diabetes; Subcutaneous administration; Effective dose
• ISSN: 0026-0495; 1532-8600
• DOI: 10.1016/S0026-0495(96)90162-6

The aim of the study was to determine the appropriate dose of subcutaneous insulin to induce “β-cell rest” without any hypoglycemic risk, as the first step in the investigation of its potential effect in preventing or delaying clinical diabetes mellitus onset in high-risk subjects. Four subjects at high risk for type I diabetes mellitus (first-degree relatives, islet cell antibodies (ICA)-positive, and with diminished first-phase insulin secretion) were compared with four healthy individuals. After hospitalization, urinary C-peptide excretion (UCP) and 24-hour serum profiles for glucose were measured before and after administration of NPH insulin 0.1, 0.2, and 0.3 U · kg body weight per day subcutaneously in a single dose on 4 consecutive days. After insulin 0.1 U · kg body weight, a significant inhibition of endogenous insulin secretion was observed in high-risk subjects, but not in control subjects. There was no further inhibition when a higher insulin dose (0.2 and 0.3) was administered. A sustained β-cell rest was obtained after 3, 6, and 12 months of treatment with 0.1 U · kg body weight per day as outpatient therapy in high-risk subjects. With this dose, no subject developed hypoglycemia (plasma glucose <50 mg/dL), whereas this adverse effect was detected after 0.2 and 0.3 U · kg body weight in both groups. In conclusion, our results indicate that administration of NPH insulin 0.1 U · kg body weight per day induces β-cell rest without the undesirable effect of hypoglycemic episodes. This is a preliminary study to investigate the potential beneficial effect of insulin in preventing or delaying type I diabetes mellitus in subjects at high risk for the disease.